妊娠期阻塞性睡眠呼吸暂停睡眠监测联合靶向自动调节气道正压治疗的随机对照试验
这项随机对照试验将193名阻塞性睡眠呼吸暂停高危孕妇分为睡眠监测筛查组(接受靶向自动调节气道正压治疗)与未筛查对照组。筛查组与对照组的复合不良妊娠结局(46.4% vs 43.3%,P=.77)及住院费用均无显著差异。作者指出样本量小、处方率低、依从性差,难以得出确定性结论,需大型多中心试验。
要点
- 高危孕妇筛查组与对照组复合不良妊娠结局无显著差异(46.4% vs 43.3%,P=.77)。
- 妊娠期及产后3个月呼吸暂停低通气指数升高,产后达峰(P<.001)。
- 自动调节气道正压依从性差,使用率为2%(1/64天)至43%(6/14天)。
核心结论
- 对阻塞性睡眠呼吸暂停高危孕妇行睡眠监测筛查并给予靶向自动调节气道正压治疗,与未筛查组相比未降低复合不良妊娠结局或住院费用。
- 作者指出样本量小、自动调节气道正压处方率低和依从性差导致难以得出确定性结论。
- 作者认为需要足够把握度的大型多中心临床试验。
研究设计与样本
- 随机对照试验,孕妇按阻塞性睡眠呼吸暂停高风险纳入,随机分为睡眠监测筛查组(接受自动调节气道正压治疗)与未筛查、接受标准产科照护的对照组。
- 筛查组在妊娠早期(6-16周)和晚期(27-33周)各接受一次睡眠监测,呼吸暂停低通气指数≥5次/小时者启动自动调节气道正压治疗。
- 两组均在产后3个月接受睡眠监测;共193名孕妇随机(筛查组100名、对照组93名),6名失访。
- 主要结局为复合不良妊娠结局,包括高血压、早产、低出生体重、死产和糖尿病;次要结局包括阻塞性睡眠呼吸暂停严重程度和住院费用。
主要发现
- 复合不良妊娠结局筛查组46.4% vs 对照组43.3%(P=.77),无显著差异。
- 高血压筛查组23.7% vs 对照组32.0%(P=.25);早产13.4% vs 10.0%(P=.5);低出生体重5.2% vs 6.7%(P=.76);死产1% vs 0%(P=1);妊娠期糖尿病19.6% vs 13.3%(P=.33)。
- 平均费用筛查组12185美元 vs 对照组12607美元。
- 呼吸暂停低通气指数在整个妊娠期升高,产后3个月达峰(P<.001);24名受试者(25.8%)新诊断阻塞性睡眠呼吸暂停,其中6名被处方自动调节气道正压。
- 自动调节气道正压依从性差,使用率范围为2%(64天中1天)至43%(14天中6天)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出样本量小、自动调节气道正压处方率低和依从性差导致难以得出确定性结论。
- 作者认为需要足够把握度的大型多中心临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obstructive sleep apnea is associated with adverse pregnancy outcomes. The impact therapy for obstructive sleep apnea has on these pregnancy outcomes remains under investigated. OBJECTIVE: This study aimed to determine the effects of targeted autoregulated positive airway pressure in women at risk of obstructive sleep apnea on adverse pregnancy outcomes, cost, and natural history of obstructive sleep apnea. STUDY DESIGN: Pregnant women at high risk of obstructive sleep apnea were randomized to either a sleep study screening group receiving autoregulated positive airway therapy or a group not screened for obstructive sleep apnea receiving standard obstetrical care (control). Women in the sleep study-screened group received a sleep study at 2 periods during pregnancy, early (6-16 weeks of gestation) and late (27-33 weeks of gestation), with initiation of autoregulated positive airway therapy if their Apnea Hypopnea Index indicated ≥5 events per hour. Women of both groups had a sleep study 3 months after delivery. The primary outcome was effect on adverse pregnancy outcomes, a composite of hypertension, preterm birth, low birthweight, stillbirth, and diabetes mellitus. The secondary outcomes included obstructive sleep apnea severity and hospital costs. RESULTS: Among 193 women randomized (100 in the sleep study-screened group and 93 in the control group; 6 lost to follow-up), there was no significant difference in composite adverse pregnancy outcomes (46.4% screened vs 43.3% control; P=.77), hypertension (23.7% screened vs 32.0% control; P=.25), preterm birth (13.4% screened vs 10.0% control; P=.5), low birthweight (5.2% screened vs 6.7% control; P=.76), stillbirth (1% screened vs 0% control; P=1), gestational diabetes (19.6% screened vs 13.3% control; P=.33), or mean cost ($12,185 screened vs $12,607 control). The Apnea Hypopnea Index increased throughout pregnancy, peaking at 3 months after delivery (P<.001). There were 24 subjects (25.8%) who had a new diagnosis of obstructive sleep apnea, with 6 in whom autoregulated positive airway was prescribed. The autoregulated positive airway compliance rates were poor with usage rates ranging from 2% (1 of 64 days) to 43% (6 of 14 days). CONCLUSION: Targeted autoregulated positive airway therapy for obstructive sleep apnea did not decrease composite adverse pregnancy outcomes or hospital costs in the sleep study-screened high-risk pregnancy group compared with the group that received no obstructive sleep apnea screening. However, a small sample size, low autoregulated positive airway prescription rates, and poor compliance resulted in difficulty in drawing a definitive conclusion. The prevalence and severity of obstructive sleep apnea worsened throughout pregnancy, with the highest rates detected in the postpartum period. Large, multicenter clinical trials that are adequately powered are needed.
引用
- Kalkhoff SM, Lutgendorf MA, Morrison TC, et al. A randomized controlled trial of sleep study surveillance with targeted autoregulated positive airway pressure therapy for obstructive sleep apnea in pregnancy. Am J Obstet Gynecol MFM. 2022. PMID: 35051670. doi:10.1016/j.ajogmf.2022.100571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。